Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp reaffirms lon term outlook - Conference Call

Tuesday, 4 Mar 2014 11:20am EST 

Celgene Corp:Says it has talked about moving product sales to that $13 -$14 bln range with EPS in the $15 range by FY 2017, significant compounded annual growth.FY 2017 revenue of $13 bln, EPS of $15 - Thomson Reuters I/B/E/S. 

Company Quote

-0.32 -0.35%
17 Sep 2014